Australia: Senate Inquiry Rejects Gene Patent Amendment Bill


After over one hundred written submissions, two days of hearings and two extensions of time in which to report, the Senate Legal and Constitutional Affairs Legislation Committee Report into the Gene Patent Amendment Bill 2010 was tabled in the Senate on 21 September 2011.

The Committee made one recommendation, namely that the Senate should not pass the Bill.


Originally, the Gene Patent Amendment Bill 2010 proposed an amendment to the Patents Act 1990 which would exclude from patentability "biological materials including their components and derivatives, whether isolated or purified or not and however made, which are identical or substantially identical to such materials as they exist in nature". Strong criticism that the terms "components", "derivatives" and "substantially identical" would introduce uncertainty into the patent system resulted in the proposed amendment being narrowed. The new proposed amendment excluded "biological materials whether isolated or purified or not and however made which are identical to such materials as they exist in nature" where "biological materials" is defined as including DNA, RNA, proteins, cells and fluids including their components; and "identical" means a biological material which is structurally and functionally identical and where any structural change or difference is immaterial to its function.

Key Issues Considered

In arriving at its recommendation, the Committee considered a number of key issues. These issues and the findings of the Committee are summarized below.

The distinction between discovery and invention

Those in support of the Bill argued that, if enacted, it would reinforce the distinction between discovery and invention in the Patents Act. However, it was clear from the evidence submitted to the Senate Inquiry that the proposed amendment would not clarify this distinction. In fact, there was evidence to suggest that, if enacted, the Bill would make the distinction between discovery and invention more obscure and, as a result, generate uncertainty within the patent system.

The Committee considered that a more preferable approach to distinguishing between discovery and invention was a recommendation made in a report by the Advisory Council on Intellectual Property (ACIP), published in February 2011. This recommendation proposed that the law currently applied by the Courts in relation to patentable subject matter - namely, that a patentable invention must be an "artificially created state of affairs" in the field of economic endeavour - be codified in the Patents Act.

The Committee also regarded favourably the proposed changes in the "Raising the Bar Bill 2011" which recommended a range of "technology neutral" changes to the Patents Act including raising the threshold for inventive step and increasing the disclosure and support requirements for patent specifications.

More information regarding the ACIP Report and the "Raising the Bar Bill" can be obtained at the following link.

Access to treatments, diagnostics and methods for healthcare

The Committee indicated in their Report that there was no evidence that patents were adversely impacting on the provision of healthcare in Australia. Moreover, it was clear from a number of submissions that enactment of the Bill would not resolve the issue that initiated the gene patent debate: namely, the potential enforcement of patent rights relating to tests to determine susceptibility to breast cancer by BRCA1 and BRCA2 gene testing. In fact, evidence was submitted that excluding biological materials from patentability would potentially have significant adverse consequences for healthcare in Australia, including delays in accessing diagnostic tests, medicines and treatments. The evidence submitted also suggested that the Bill would limit access to clinical trials for Australian patients as well as reduce investment in medical research and development in Australia.

Freedom to research

The proponents of gene patent reform argued that the Bill would provide certainty for scientists conducting research on biological material. However, the Committee did not agree with this view.

The Committee believed that a preferable approach to providing certainty for researchers was a general research exemption as proposed in the "Raising the Bar Bill". This proposed exemption would result in research and experimental activities relating to patented inventions being exempt from infringement.

Investment in Research and Development

On the basis of the evidence submitted to the Inquiry, the Committee concluded that patents directed to biological materials have not hindered research, particularly medical research. In fact, evidence was presented indicating that patents had in fact encouraged and contributed to research and development activities by, for example, attracting investment funds.

The Committee concluded that the Bill would have significant implications for a broad range of industries including healthcare, pharmaceuticals, agriculture, food manufacturing and biotechnology. Coupled with the imprecise language of the Bill, the Committee believed that it would potentially discourage investment in research and development and encourage litigation by those seeking to clarify patent rights.

It was also indicated in the Report that without certainty in relation to patent protection for biological materials, companies would have less incentive to develop and commercialise new products for the Australian market or, alternatively, a greater incentive not to publicly disclose inventions.

Ethical considerations

The Committee was cognisant of the fact that the patenting of biological material may be challenged on ethical grounds. However, the Committee considered that the proposal in the ACIP Report for an exclusion to the grant of patents which would be perceived as unethical by the community was preferable to a broad exclusion of biological material.

International considerations

Both sides of the gene patent debate have used Australia's obligations under the TRIPS agreement (which requires patenting in all fields of technology) to support their arguments. On the one hand, the proponents of gene patent reform argue that as isolated biological materials are not "inventions", excluding such subject matter from patentability would not contravene Australia's obligations under the TRIPS agreement. On the other hand, those opposed to the Bill argued that isolated biological materials represent an artificially created state of affairs and therefore can be considered inventions. Accordingly, excluding such material from patentability would contravene Australia's obligations under the TRIPS agreement.

Ultimately, the Committee believed that enacting the Bill would potentially breach Australia's obligations under the TRIPS agreement.

Dissenting Report

A dissenting view expressed by Senators Heffernan, Siewert and Xenophon (staunch supporters of gene patent reform) was also included in the Report. The dissenting view makes reference to a range of perceived potential problems in the Australian patent system. However, it is clear from the evidence submitted during the Senate Inquiry that the Bill would not provide solutions to these perceived problems. A more rational view and one that was expressed consistently by the majority of the Committee is that a number of technology-neutral recommendations by the ACIP Report and the "Raising the Bar Bill" will be more effective in addressing the perceived problems with the current Australian patent system.


The Committee agreed that that although the Bill was "well intentioned" it did not represent an effective solution to any potential or perceived problems that may be caused by the patenting of biological material. In fact, the Committee believed that if the Bill was enacted it would result in a large number of adverse consequences across the patent system which would impact a range of industries and healthcare sectors.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Grant Shoebridge
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.